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Abstract
Pharmacological inhibition of cardiac hERG K
+ channels is associated with increased risk of lethal arrhythmias. Many drugs
reduce hERG current by directly binding to the channel, thereby blocking ion conduction. Mutation of two aromatic
residues (F656 and Y652) substantially decreases the potency of numerous structurally diverse compounds. Nevertheless,
some drugs are only weakly affected by mutation Y652A. In this study we utilize molecular dynamics simulations and
docking studies to analyze the different effects of mutation Y652A on a selected number of hERG blockers. MD simulations
reveal conformational changes in the binding site induced by mutation Y652A. Loss of p-p-stacking between the two
aromatic residues induces a conformational change of the F656 side chain from a cavity facing to cavity lining orientation.
Docking studies and MD simulations qualitatively reproduce the diverse experimentally observed modulatory effects of
mutation Y652A and provide a new structural interpretation for the sensitivity differences.
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Introduction
HERG (human ether-a-go-go related gene) encodes the pore-
forming subunit of the voltage-gated potassium channel IKr expressed
in the heart and in nervous tissue [1]. The channel contributes to
modulation of the repolarization phase III of the myocyte action
potential [1–3]. Disruption of hERG channel function, due to
inherited mutations [4], [5], or side effects of drugs, has been linked to
long QT syndrome (LQTS) [6], which may lead to serious
arrhythmia and sudden cardiac death [7], [8]. This phenomenon is
caused by structurally diverse therapeutic compounds including
antiarrhythmics, antihistamines, antipsychotics and antibiotics [9].
Several compounds like terfenadine (SeldaneH)a n dc i s a p r i d e
(PropulsidH) had to be withdrawn from the market for this reason.
Consequently, there is an intense interest in understanding the
molecular and structural mechanisms of hERG channel gating and
block. Individual mutations of pore forming residues to alanine
revealed amino acids essential for drug binding. Residues T623, S624
and V625,located atthe bottom of the porehelix,and residuesG648,
Y652 and F656, located in S6 segments are important binding
determinants for many drugs from diverse chemical classes [1], [10–
21]. Mutations of Y652 and F656 to alanine resulted in 94-fold and
650-fold block decrease for compound MK-499, respectively [10].
Similarstrongeffectshavebeenfoundformanystructurallyunrelated
compounds such as cisapride and terfenadine, suggesting a common
binding region within the aqueous inner cavity [22].
Homology models [23–27] suggest that high affinity binding
determinants Y652 and F656 are arranged in two aromatic rings,
facing the inner cavity (Fig. 1). p-p-stacking interactions as well as
cation-p-interactions with these residues have been proposed to
play a crucial role for block [28]. The importance of the aromatic
side chain at position Y652 is further supported by mutational
studies, indicating that conservative mutations Y652F and Y652W
retain normal sensitivity to high affinity blockers MK-499 and
cisapride [10] while non-aromatic substitutions strongly diminish
block. In contrast, at position F656 hydrophobicity seems sufficient
for high affinity block [16].
The binding mode for blockers such as bepridil, thioridazine or
fluvoxamine differs with respect to Y652. These compounds are
only partially attenuated by mutation Y652A [22], [28–30].
Nevertheless, with the exception of fluvoxamine [28], drugs are
strongly attenuated by mutation F656A, suggesting that they bind
in the inner cavity [12], [31]. In 2009, Xing et al. [32] found that
capsaicin, a pungent irritant occurring in peppers, enhances
hERG block upon mutation of Y652A 4-fold, while F656 was
suggested to be relatively unimportant for block.
The mechanism by which these drugs interact with hERG
channels is largely unknown. Thus, we investigated whether bepridil,
thioridazine, propafenone and capsaicin have different binding modes
compared to cisapride, dofetilide, E-4031, MK-499, terfenadine or
ibutilide. In this study we utilized MD simulations and docking studies
to investigate the different role of Y652 on drug binding.
Results
Flexibility of putative aromatic binding residues in the
hERG cavity
A recently validated homology model of the open hERG pore
(model 6 of Stary et al. [26]) was used as starting point for our
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28778analyses. Y652 and F656 belong to a cluster of four aromatic
residues, which includes F557 located on helix S5 and F619 from
the P segment (Figure 1A). The conformational flexibility of these
aromatic side chains was analyzed using molecular dynamics
simulations. Figure 1B–C shows the distribution of dihedral angles
x1 (rotation around Ca–Cb atoms) and x2 (rotation around Cb–
Cc atoms) for side chains Y652 and F656 on a 50 ns time scale.
Since our sampling protocol involved sampling at 10 ps intervals
and each channel contains four homologous domains, each plot
contains 20,000 black dots representing the conformations
observed in the simulation. Figure 1B illustrates the rigidity of
the Y652 side chain on the nanosecond time scale. Variations are
observed for the dihedral angle x2 only. The F656 side chain is
more mobile, it can adopt various x1 and x2 conformations. The
multiple observed conformational states suggest inherited flexibil-
ity at position F656 in the open conformation. The side chain of
F557, which is not part of the drug binding site, is relatively rigid.
The phenyl ring of F619 from the P-helix adopts various x1 and x2
conformations (see Figure S1A–B).
Conformational changes induced by alanine mutations
The structural effects of mutations Y652A and F656A were
examined using MD simulations. First, in silico mutants were
generated using the mutagenesis tool in PyMOL, followed by
energy-minimizations. Repeated simulations on a 50 ns time scale
were performed. The stability of the mutant channels, measured as
the root mean square deviation (RMSD) as a function of time is
shown in Figure 2A. The values for WT and Y652 are in the range
of 0.25 nm, the RMSD for the F656A mutant is slightly higher; it
reaches 0.3 nm after 50 ns. The increased RMSD is not due to
stability differences in S6 helices (Figure 2C) but due to less stable
loops connecting S5 and P helix (Figure 2B).
Replacement of the planar aromatic moiety in position Y652
altered the conformation of residue F656, which was stabilized by
parallel displaced p-p-stacking interactions in WT. Calculations by
Tsuzuki et al. [33], indicate that the energy contribution for this
type of aromatic-aromatic interactions is in the range of
21.48 kcal/mol. Due to the loss of these interactions in the
Y652A mutant the side chain of F656 rotated away from the pore
axis allowing edge to edge shaped p-p-stacking interactions with
F557 from the neighboring S5 segment (see Figure 3A–C). The
interaction energies of edge to edge p-p-stacking are approxi-
mately 1 kcal/mol stronger than parallel displaced p-p-stacking
(22.48 kcal/mol vs. 21.48 kcal/mol [33]). Figure 3D compares
the x1 angle of side chain F656 in WT and Y652A mutant
channels as a function of time. The x1 angle is predominantly in
Figure 1. Location and flexibility of putative aromatic binding residues in hERG. (A) p-p-stacking interactions between binding
determinants Y652 and F656, located on helix S6 and residues F619 (P-helix) and F557 (S5 helix). Side chains are shown as green sticks (B). x1/x2 plot
of Y652 and F656 (C) obtained from 50 ns MD simulations.
doi:10.1371/journal.pone.0028778.g001
Figure 2. Stability of WT and mutant hERG channels. (A) Backbone RMSD of the Y652A (blue) and the F656A mutant (brown) compared to WT
channel (black). (B) Comparison of the root mean square fluctuations (RMSF) for WT and mutant channels. Only the P-helix and connecting loops are
shown. (C) RMSF of S6 helix.
doi:10.1371/journal.pone.0028778.g002
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mutant channel this value is changed to 260u to 60u. The more
favorable edge to edge stacking energy might explain why the
F656 side chain adopted a gauche(2) conformation in 80% of the
simulations. Gauche(+) and trans conformations were rarely
observed (results for the rerun are shown in Figure S3).
MD simulations on the F656A mutant did not reveal significant
conformational changes of aromatic residues compared to WT
(see Figure S1A–C). Therefore, this mutant was not analyzed
further.
Docking studies on WT and Y652A mutant channels
We next analyzed the effects of the Y652A mutant induced side
chain orientation of residue F656 on drug block. Eleven drugs
(Figure 4 and Figure 5) were docked into 20 WT and 20 Y652A
snapshots (every 5 ns from two independent runs) derived from
50 ns MD simulations. For each blocker, the ten most frequent
occurring docking poses of each drug (n=100) were analyzed with
respect to aromatic ring stacking and/or hydrophobic interactions
with binding residues Y652 and F656. Table 1 summarizes these
interactions and lists the number of t-shaped (t), edge-to-edge (e)
and parallel p-p-stacking (p) interactions. Gold Chemscores
(Gold.Chemscore.DG) are listed in Table 2.
Drugs can be divided into three groups according to their
binding behavior. For drugs that have been shown to be only
partially attenuated by a tyrosine to alanine mutation in position
652 [22], [28–30], no or slight changes in binding behavior
compared to WT were observed (Table 1 and Figure 5). The
binding mode for thioridazine was identical in WT and Y652A.
Three aromatic interactions were predicted in both cases
(Figure 5). Docking studies with bepridil suggested that the total
number of aromatic interactions remained constant in the mutant
channel. However, in the WT channel this drug formed one
parallel p-p-stacking interaction with Y652 and one edge-to-edge
interaction, while in the Y652A mutant channel, two edge-to-edge
interactions with F656 were predicted (Figure 5). The number of
aromatic interactions for propafenone and GPV009 did not
change in Y652A. The only modification observed was a change
of one t-shaped to an edge-to-edge stacking interaction with
propafenone.
Figure 3. Side chain rearrangements of F656 induced by mutation Y652A. (A) x1/x2 side-chain angles of F656 for WT (black) and Y652A
(blue). The green and blue arrows indicate the approximate conformations of the F656 side chains shown in B and C. (B) Representative side-chain
conformations of WT and Y652A mutant (C) channel snapshots taken from MD simulations. (D) F656 x1 dihedral angles for WT (black) and Y652A
(blue) in all four domains as a function of time.
doi:10.1371/journal.pone.0028778.g003
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4031, ibutilide, MK-499 and terfenadine were predicted to
strongly interact with aromatic side chains Y652 and F656. While
several favorable aromatic interactions to both aromatic side
chains were predicted for cisapride and MK-499 in the WT
channel, docking studies performed with the Y652A mutant
channel indicated complete loss of aromatic interactions. All other
drugs in this group had drastically reduced aromatic and
hydrophobic interactions with F656 in the Y652A mutant
channel. For example, in the WT channel terfenadine was
predicted to interact with Y652 side chains from three domains
and two F656 residues. In the mutant channel only one edge-to-
edge interaction with the F656 side chain remained (see Figure 5
and Figure S2).
Important changes between the Y652A sensitive and Y652A
insensitive drug groups were also observed considering the
conformation of the drugs. Docking results suggest that thiorid-
azine, bepridil, propafenone and GPV009 fold mostly into U-
shaped conformations, while extended conformations parallel to
the pore axis were not observed in either WT or Y652A mutant
channel. In contrast, most drugs that are highly sensitive to
mutation Y652A change their conformation from U-shaped in the
WT channel to a stretched conformation longitudinal to the
channel axis (Figure 5).
Figure 4. Structures of hERG blockers examined in this study. Drugs are clustered into three groups: group 1 (orange frame) includes
blockers which are relatively insensitive to mutation Y652A
22,28–30, group 2 (green frame) shows Y652 sensitive drugs
10,18,22,31 and group 3 (blue
frame) shows capsaicin whose affinity is increased by mutation Y652A
32.
doi:10.1371/journal.pone.0028778.g004
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affected by the Y652A mutation in a different way. To the best of
our knowledge, it is currently the only known drug that shows
increased affinity for the Y652A mutant. Gold predicted one
aromatic interaction (parallel or edge-to-edge) for WT and Y652A,
respectively. Docking suggests that the number of hydrogen bonds
with selectivity filter residues T623 and S624 increased in the
mutant channel (two H-bonds to T623 and one H-bond to S624).
In the WT channel only two hydrogen bonds between capsaicin
and S624 were predicted (Figure 6).
MD simulations support different drug binding modes in
WT and Y652A channels
To further support our hypothesis, 10 ns MD simulations on all
docked poses shown in Figure 5 and Figure S2 were performed.
Generally, the docked binding poses are stable on the nanosecond
time scale. The Y652A insensitive compounds bepridil, thiorida-
zine, propafenone, and GPV009 retain their compact binding
mode in the channel pore in WT and Y652A mutant channels
(Figure 5A–F, Figure S2A–B). For the drugs which are sensitive to
mutation Y652A, simulations strongly support the suggested drug
rearrangement from the horizontal binding mode in WT to a
stretched conformation along the channel axis in the mutants
(Figure 5G–L, Figure S2C–H). This provides a possible explana-
tion for the experimentally observed affinity loss. Only E-4031
does not remain stable in the Y652A mutant (Figure 5J).
Additionally, MD simulations reveal which functional groups of
the compounds are flexible. For example, while the basic scaffold
of the propafenone molecule (acylphenyloxypropanolamine)
remains rather rigid, the side chain adopts various conformations.
The movies S1, S2, S3, S4, S5, S6, S7, S8, S9, and S10 show the
behavior of all ten drugs in WT and mutant channels during the
10 ns MD simulation runs.
Surprisingly, the conformational flexibility of the Y652 and
F656 side chains is not influenced when drugs reside in the cavity
(for examples see Figure S6). In contrast, conformational changes
of the aromatic side chains sometimes induce changes in drug
orientation (for example see behavior of E-4031 in the movie S5).
Discussion
Direct block of hERG channels by structurally diverse drugs is
mediated by aromatic side chains Y652 and F656 (see Figure 1 for
Figure 5. Docking (cyan transparent sticks) and MD poses. at the end of the simulation (blue sticks) of bepridil (AB), thioridazine (CD),
propafenone (EF), cisapride (GH), terfenadine (IJ) and ibutilide (KL) in WT and Y652A (from left to right). Y652 and F656 are shown as green lines; A652
is shown as orange lines. The arrow displays the movement of the heptyl chain of ibutilide.
doi:10.1371/journal.pone.0028778.g005
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dramatically reduces drug potency, implying a direct interaction
with these residues. In agreement with this hypothesis, various
drug docking studies predict binding modes, favoring p-p-stacking
interactions with Y652 and F656.
More recently, compounds have been identified, which are
insensitive to mutation Y652A, while displaying greatly reduced
affinity for the F656A mutant [22], [28], [29]. The lack of
sensitivity of these molecules could simply result from binding ‘‘less
deeply’’ in the cavity, possibly below the position of Y652.
Alternatively, replacement of Y652 might induce allosteric effects
on drug binding rather than directly disrupting binding. For the
reasons discussed in detail below, we favor the second hypothesis.
Our MD simulations suggest that deletion of the aromatic side
chain in position Y652 induces allosteric changes in the drug
binding site, with important consequences for drug binding.
Specifically, loss of p-p-stacking interactions induce a conforma-
tional change of the F656 sidechain from a cavity facingorientation
(x1 values in the range of 2180u) to a cavity lining conformation (x1
values in the range of 260u) (compare Figure 1A–C and 3A–C).
This conformation is stabilized by energetically favorable edge-to-
edge stacking interactions with the F557 aryl ring, located on helix
S5. Docking studies comparing the binding modes of 11 hERG
blockers revealed different behavior for rigid compact molecules
versus compounds with more extended geometries. Only the first
class of drugs could still favorably interact with the reoriented F656
residues from several subunits in the Y652A mutant (Figure 5,
Table 1 and Figure S2). These results correlate well with
experimental Y652A sensitivities and are in agreement with a
ligand based hypothesis by Stansfeld et al. [34], [35] derived from a
study of 20 LQT compounds with varying Y652A sensitivities.
Besides, the importance of the orientation of the Y652 and F656
side chains for high affinity block has been elegantly demonstrated
by Chen et al. [36] Their study showed that the decreased drug
affinity of non-inactivating hERG mutant channels is not caused by
inactivation per se but by inactivation gating-associated reorienta-
tion of residues located in the S6 domain.
It has been reported by Zachariae et al. [37] that longer
molecules bind in a perpendicular orientation to the channel axis
and therefore may interact with all four domains of the channel. In
our WT drug docking studies we observe the same perpendicular
positioning. In the Y652A mutant, the orientation of extended
compounds, sensitive to mutation of Y652 is changed to a
stretched conformation parallel to the channel axis. These drug
reorientations in the Y652A mutant are further supported by a
total of 200 ns (10 and for WT and mutants, respectively) MD
simulations.
In contrast to an interesting study by Huang et al. [38], who
observed an induced fit of a toxin binding to the extracellular side
of the selectivity filter in a shaker K
+ channel, we did not see
conformational adaptions of Y652 or F656 upon drug binding to
the hERG inner cavity (Figure S5). This suggests different drug
receptor interactions for different binding sites, which might be in
part explained by the different nature of interactions (mainly
electrostatic versus mainly aromatic/hydrophobic). Interestingly,
conformational changes of the aromatic side chains sometimes
even induce changes in drug orientation (see movies S1, S2, S3,
S4, S5, S6, S7, S8, S9, and S10).
In a recent review by Zhou et al. [39], it was pointed out that
aromatic side chains are predestinated to serve as channel gates,
preventing ion flow in the closed conformation. Detailed
inspection of our recently published closed hERG homology
model [40] indeed reveals an optimal arrangement of the F656
Table 1. Aromatic ring stacking and hydrophobic
interactions (HIA) between Y652 and F656 side chains and
hERG antagonists in WT and Y652A mutant channels.
Compound WT Y652A
Y652 F656 g HIA A652 F656 g HIA
Thioridazine - 3 (t,p,e) 3 - 3 (t,p,e) 3
Bepridil 1( p ) 1( e ) 2 - 2( e ) 2
Propafenone 2 (t,e) 2 (t,e) 4 - 2 (e) 2
GPV0009 3 (t,2e) 1 (e) 4 - 1 (e) 1
Capsaicin - 1 (p) 1 - 1 (e) 1
Cisapride 2 (p,e) 2 (t,p) 4 - - 0
Dofetilide 2 (t,e) 2 (p,e) 4 - 1 (e) 1
E-4031 3 (t,2e) 2 (e) 5 - 2 (p,e) 2
Ibutilide 3( e ) - 3 - 1( p ) 1
MK-499 1( e ) 1( e ) 2 - - 0
Terfenadine 3 (t,2e) 2 (t,e) 5 - 1 (e) 1
(t=T-shaped stacking, p=parallel p-p-stacking, e=edge-to-edge interactions).
doi:10.1371/journal.pone.0028778.t001
Table 2. Free energies of binding calculated by Chemscore
(DG
bind kJ/mol) for WT and Y652A.
Drug
Chemscore
WT
Chemscore
Y652A
Difference
WT vs Y652A
Thioridazine 230.67 227.83 22.84
Bepridil 232.92 231.23 21.69
Propafenone 232.88 229.75 23.13
GPV0009 235.51 231.43 24.08
Capsaicin 231.34 232.85 1.51
Cisapride 230.86 222.96 27.90
Dofetilide 230.00 220.67 29.33
E-4031 235.59 222.82 212.77
Ibutilide 233.69 221.52 212.17
MK-499 230.18 223.19 26.99
Terfenadine 235.21 230.51 24.70
doi:10.1371/journal.pone.0028778.t002
Figure 6. Interactions of capsaicin with the selectivity filter in
WT (A) and Y652A mutant (B). Selectivity filter residues involved in
capsaicin binding are shown as green sticks; residues of the TSV motif
not interacting with capsaicin are shown as grey lines. Hydrogen bonds
are depicted as black dots.
doi:10.1371/journal.pone.0028778.g006
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reorientations in the Y652A mutant most likely do not influence
ion conductance in the open state, however we cannot exclude
gating-associated reorientations. It was beyond the scope of the
current study to analyze mutation induced effects in the closed
channel state. Nevertheless, future studies might provide an
answer to this important question.
To further support the allosteric side chain rearrangement
hypothesis, we introduced a phenylalanine at position Y652,
which was shown to restore WT-like binding behavior for the high
affinity compound MK-499 [20]. MD simulations show that in the
Y652F mutant the aromatic side chains of F557, F619 and F656
behave similar as in the WT channel (see Figure S4A–D). In
agreement with experimental data, we find similar docking poses
for WT and Y652F channels with compound MK-499.
Allosteric effects on drug block are also used to explain the
effects of several inactivation deficient mutants on hERG block.
For example, inactivation deficient mutants N588K and S620T
exhibit reduced affinity for dofetilide and other high affinity
blockers [41]. However, none of these residues is assumed to
directly interact with these compounds, since both are located
distantly from the binding site.
In conclusion, MD simulations of WT and Y652A mutant
channels in combination with drug docking provide a new
structural interpretation for the diverse modulatory effects of
residue Y652 on different hERG blockers ranging from strong
affinity decrease (e.g. cisapride) upon mutation to affinity increase
in the case of capsaicin. The results provide a starting point for
future investigations focusing on further residues of the aromatic
cluster in the hERG binding site. For example, studies on mutants
of F557 and F619 will provide a better understanding of the still
poorly described mechanisms underlying hERG block.
Materials and Methods
Molecular dynamics simulations
MD simulations were performed with Gromacs v.4.5.4. [42]
Two independent simulation setups using either the OPLS-all-
atom force field [43] or the amber99sb force field [44] were used
to analyze the dynamics of hERG WT and mutant channels.
Mutants Y652A, Y652F and F656A were generated using the
mutagenesis tool in PyMOL 0.99 [45] In the OPLS setup, hERG
WT and mutant channels were embedded in an equilibrated
simulation box of 241 palmitoyloleoylphosphatidylcholine (POPC)
lipids. The channels were inserted into the membrane as described
previously [26]. K
+ ions were placed in the channel at K
+ sites S0,
S2, and S4, with waters placed at S1 and S3 of the selectivity filter
[46]. Cl
2 ions were added randomly within the solvent to
neutralize the system. Lipid parameters were taken from Berger
et al. [47]. The solvent was described by the TIP4P water model
[48]. Electrostatic interactions were calculated explicitly at a
distance ,1 nm and long-range electrostatic interactions were
calculated at every step by particle-mesh Ewald summation [49].
Lennard–Jones interactions were calculated with a cutoff of 1 nm.
All bonds were constrained by using the LINCS algorithm [50],
allowing for an integration time step of 2 fs. The Nose-Hoover
thermostat was used to keep simulation temperature constant by
weakly (t=0.1 ps) coupling the lipids, protein and solvent
(water+counter-ions) separately to a temperature bath of 300 K.
The pressure was kept constant by weakly coupling the system to a
pressure bath of 1 bar using a semi-isotropic Parrinello-Rahman
barostat algorithm with a coupling constant of 1 ps. Prior to
simulations, 1000 conjugate gradient energy-minimization steps
were performed, followed by 2 ns of restrained MD in which the
protein atoms were restrained with a force constant of 1000 kJ/
mol
21 nm
22 to their initial position. Ions, lipids and solvent were
allowed to move freely during equilibration. The systems were
then subjected to 50 ns (15 ns Y652F) of unrestrained MD, during
which coordinates were saved every 10 ps for analysis. Residues at
the N- and C-termini were considered as uncharged, as neither lie
at the actual termini of the complete channel. In the amber99sb
setup hERG WT and mutant channels were embedded in an
equilibrated membrane consisting of 280 dioleolylphosphatidyl-
choline (DOPC) lipids. Lipid parameters were taken from Siu,
et al. [51] and the TIP3P water model [48] was utilized. All further
parameters and steps were carried out as described above. Drug
topologies were generated using antechamber, which is part of the
Amber 11 program package [52]. Charges were taken from
Gaussian runs described in the docking section below. After
energy-minimization (1000 conjugate gradient energy-minimiza-
tion steps), unrestrained 10 ns MD simulations for each compound
were carried out for WT and Y652A (200 ns in total) at 310 K.
Drug docking
Coordinates of the drugs were generated with Gaussview 5 [53]
and the geometry optimized with HF/3-21G implemented in
Gaussian09 [53]. For thioridazine, propafenone, GPV009,
terfenadine, MK-499 and ibutilide (R)- and (S)-conformations
were docked. As no differences could be observed between both
enantiomers, only the (R)-conformation was used for further
analysis. Docking was performed with the program Gold 4.0.1
[54] using the Gold and Chemscore scoring functions. The
coordinates of the geometric center calculated among the Y652
and F656 residues were taken as binding site origin. The binding
site radius was set equal to 10 A ˚. 100,000 operations of the GOLD
genetic algorithm were used to dock the selected compounds into
the WT and mutant channels. Snapshots after 8, 10, 15, 20, 25,
30, 35, 40, 45 and 50 ns were taken from our 50 ns or 15 ns
(Y652F) MD trajectories. The best ranked 100 poses of each
docking run were used for visual analysis of binding. From the ten
most occurring positions the numbers of aromatic interactions
were averaged.
Supporting Information
Figure S1 x1/x2 plots for F557 (A), F619 (B) and Y652 (C)
in hERG WT channel (black) and F656A (brown).
(TIF)
Figure S2 GPV009 (AB), MK-499 (CD), E-4031 (EF) and
dofetilide (GH) in WT and Y652A (from left to right).
Cyan transparent sticks show the docking pose and blue sticks the
MD pose and the end of the simulation. The black arrow indicates
the moving direction of E-4031 (the dynamical movement of the
drug can be observed in the attached movie).
(TIF)
Figure S3 MD simulation rerun (50 ns) for Y652A
mutant. RMSD plot (A), x1/x2 plot for F656 (B) and the
F656 x1 dihedral angles in all four domains as a function
of time (C) show no significant deviation from the
original run.
(TIF)
Figure S4 x1/x2 plots for F557 (A), F619 (B), Y/F652 (C)
and F656 (D) in hERG WT channel (black) and Y652F
(green). The 50 ns MD simulation shows that the flexibility of
the aromatic side chains in the mutant is comparable to the WT
channel.
(TIF)
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28778Figure S5 Y652 (A) and F656 (B) x1 dihedral angles as a
function of time for WT channel without ligand (black)
and with bound bepridil (blue) and dofetilide (red). C
shows the x1 dihedral angles of F656 in the Y652A mutant as a
function of time.
(TIFF)
Movie S1 Behavior of docked drug cisapride in a 10 ns
MD simulation. In the first part of the movie, the drug behavior
in the WT is shown, followed by the Y652A mutant simulation.
Y652 and F656 are shown as green lines; A652 is shown as orange
lines.
(WMV)
Movie S2 Behavior of docked drug terfenadine in a
10 ns MD simulation. In the first part of the movie, the drug
behavior in the WT is shown, followed by the Y652A mutant
simulation. Y652 and F656 are shown as green lines; A652 is
shown as orange lines.
(WMV)
Movie S3 Behavior of docked drug ibutilide in a 10 ns
MD simulation. In the first part of the movie, the drug behavior
in the WT is shown, followed by the Y652A mutant simulation.
Y652 and F656 are shown as green lines; A652 is shown as orange
lines.
(WMV)
Movie S4 Behavior of docked drug MK-499 in a 10 ns
MD simulation. In the first part of the movie, the drug behavior
in the WT is shown, followed by the Y652A mutant simulation.
Y652 and F656 are shown as green lines; A652 is shown as orange
lines.
(WMV)
Movie S5 Behavior of docked drug E-4031 in a 10 ns MD
simulation. In the first part of the movie, the drug behavior in
the WT is shown, followed by the Y652A mutant simulation. Y652
and F656 are shown as green lines; A652 is shown as orange lines.
(WMV)
Movie S6 Behavior of docked drug dofetilide in a 10 ns
MD simulation. In the first part of the movie, the drug behavior
in the WT is shown, followed by the Y652A mutant simulation.
Y652 and F656 are shown as green lines; A652 is shown as orange
lines.
(WMV)
Movie S7 Behavior of docked drug bepridil in a 10 ns
MD simulation. In the first part of the movie, the drug behavior
in the WT is shown, followed by the Y652A mutant simulation.
Y652 and F656 are shown as green lines; A652 is shown as orange
lines.
(WMV)
Movie S8 Behavior of docked drug thioridazine in a
10 ns MD simulation. In the first part of the movie, the drug
behavior in the WT is shown, followed by the Y652A mutant
simulation. Y652 and F656 are shown as green lines; A652 is
shown as orange lines.
(WMV)
Movie S9 Behavior of docked drug propafenone in a
10 ns MD simulation. In the first part of the movie, the drug
behavior in the WT is shown, followed by the Y652A mutant
simulation. Y652 and F656 are shown as green lines; A652 is
shown as orange lines.
(WMV)
Movie S10 Behavior of docked drug GPV0009 in a 10 ns
MD simulation. In the first part of the movie, the drug behavior
in the WT is shown, followed by the Y652A mutant simulation.
Y652 and F656 are shown as green lines; A652 is shown as orange
lines.
(WMV)
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